New hope for ITP patients when first treatment fails
NCT ID NCT07476846
Summary
This study aims to find the best next-step treatment for ITP patients whose initial platelet-boosting medication didn't work. Researchers will compare switching to a double dose of the original drug (rhTPO) versus switching to a different medication (eltrombopag). The study will enroll 112 patients to see which approach better raises platelet counts and reduces bleeding risk over 6 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.